What is CANMAB 440MG?

CANMAB 440MG is a monoclonal antibody medication that contains Trastuzumab as the active ingredient. It is used in the treatment of HER2-positive cancers, specifically breast cancer and metastatic gastric cancer. CANMAB is a biosimilar version of Herceptin, developed by Biocon Biologics India Ltd.

What is the use of CANMAB 440MG?

CANMAB 440MG is used to treat:

• HER2-positive early breast cancer (in combination with chemotherapy)

• HER2-positive metastatic breast cancer (as a single agent or with other therapies)

• HER2-positive metastatic gastric cancer (in combination with chemotherapy)

It works by targeting the HER2 receptor, which is overexpressed in some cancer cells, thereby blocking cell growth and triggering immune system destruction of those cells.

Benefits of CANMAB 440MG:

• Targeted therapy: Acts specifically on HER2-positive cancer cells, reducing damage to normal cells

• Improves survival rates: Shown to improve progression-free and overall survival in HER2-positive cancer patients

• Biosimilar to Herceptin: Offers a more cost-effective alternative with comparable efficacy and safety

• Can be used in adjuvant, neoadjuvant, or metastatic settings

• Reduces tumor recurrence risk when used in early breast cancer

Side Effects of CANMAB 440MG:

While effective, CANMAB may cause side effects. These can be:

Common Side Effects:

• Fever, chills, weakness

• Nausea, vomiting

• Diarrhea

• Headache

• Rash

• Infusion-related reactions

Serious Side Effects:

• Cardiotoxicity (reduced heart function, especially in patients with previous heart conditions or concurrent anthracyclines)

• Severe infusion reactions including breathlessness, low blood pressure

• Allergic reactions

• Liver enzyme changes

1. What is CANMAB 440MG used for?
   CANMAB 440MG is used to treat HER2-positive breast cancer and HER2-positive metastatic gastric cancer, either alone or in combination with chemotherapy.

2. What is the active ingredient in CANMAB 440MG?
   The active ingredient is Trastuzumab, a monoclonal antibody that targets the HER2 protein on cancer cells.

3. How does CANMAB 440MG work?
   It binds to the HER2 receptors on cancer cells, blocking their growth and activating the immune system to destroy them.

4. Is CANMAB 440MG the same as Herceptin?
   Yes, CANMAB is a biosimilar of Herceptin, meaning it has similar efficacy, safety, and quality but is typically more affordable.

5. How is CANMAB 440MG administered?
   It is given as an intravenous (IV) infusion in a clinical setting by trained medical professionals.

6. How often is CANMAB 440MG given?
   Typically, it is given every 1 to 3 weeks, depending on the treatment plan, type of cancer, and response to therapy.

7. What are the common side effects of CANMAB 440MG?
   Common side effects include fever, chills, nausea, headache, rash, and fatigue, especially during the first infusion.

8. What are the serious risks associated with CANMAB 440MG?
   Serious risks include heart problems (cardiotoxicity), infusion-related reactions, and severe allergic responses.

9. Is heart monitoring needed during treatment with CANMAB 440MG?
   Yes. Patients need regular cardiac evaluations (like echocardiograms) before and during treatment to monitor heart health.

10. Can CANMAB 440MG be used during pregnancy?
    No, it is not recommended during pregnancy due to the risk of harm to the unborn baby. Effective contraception is advised.

11. Can CANMAB 440MG be used while breastfeeding?
    Breastfeeding is not recommended during treatment and for 7 months after the last dose due to potential risk to the infant.

12. Can CANMAB 440MG be taken with other chemotherapy drugs?
    Yes, it is often used in combination with drugs like Paclitaxel, Docetaxel, or Carboplatin to enhance treatment outcomes.

13. What happens if a dose of CANMAB 440MG is missed?
    If a dose is missed, it should be rescheduled as soon as possible under medical guidance. Do not self-administer.

14. Is CANMAB 440MG suitable for all breast cancer patients?
    No. It is only effective for patients whose tumors overexpress HER2. HER2 testing is required before starting treatment.

15. How long can treatment with CANMAB 440MG continue?
    Treatment duration varies but can continue for up to one year or more, based on patient response and tolerance.